Menopausal symptoms in young survivors of breast cancer: A growing problem without an ideal solution

Cancer Control

Volumn 19, Issue 4, 2012, Pages 317-329

  Murthy, Vijayashree ^a   Chamberlain, Ronald S ^a,b,c  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b ST GEORGE S UNIVERSITY SCHOOL OF MEDICINE   (Grenada)

^c University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; ANGELICA SINENSIS EXTRACT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPIVACAINE; CALCIUM; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN; FLUOROURACIL; FLUOXETINE; FOLLITROPIN; GABAPENTIN; GESTAGEN; HOMEOPATHIC AGENT; ISOFLAVONE; METHOTREXATE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG; VENLAFAXINE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; AEROBIC EXERCISE; AMENORRHEA; ANOREXIA; ARTICLE; BEHAVIOR MODIFICATION; BONE DENSITY; BREAST CANCER; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CONSTIPATION; DIET RESTRICTION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPAREUNIA; EVIDENCE BASED MEDICINE; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; KINESIOTHERAPY; LIBIDO DISORDER; LIFESTYLE MODIFICATION; MEDLINE; MENOPAUSAL SYNDROME; MENSTRUAL IRREGULARITY; MOOD CHANGE; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SOMNOLENCE; STELLATE GANGLION BLOCK; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS; VAGINAL PRURITUS; VASOMOTOR DISORDER; WEIGHT BEARING; WEIGHT CONTROL; XEROSTOMIA; YOGA;

EID: 84867022523     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900408     Document Type: Article

References (98)

1. American Cancer Society. Cancer Facts and Figures 2010. http://www.cancer.org/STT/Cancer_Facts_and_Figures_2010.pdf. Accessed June 19, 2012.
2. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6(5):213-218.
3. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.
4. Valdivieso M, Kujawa AM, Jones T, Baker LH. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci. 2012; 9(2):163-173.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed June 19, 2012.
6. Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21(22): 4184-4193.
7. Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med. 2011;8(1):294-302.
8. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000;343(15):1086-1094.
9. Brincker H, Mouridsen HT, Andersen KW, et al. Castration induced by cytotoxic chemotherapy. J Clin Oncol. 1989;7(5):679-680.
10. Tormey DC, Gray R, Gilchrist K, et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer. 1990;65(2):200-206.
11. Del Mastro L, Venturini M, Sertoli MR, et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997;43(2):183-190.
12. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169(1-2):123-131.
13. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and-B as markers. Mol Cell Endocrinol. 2002;187(1-2): 93-105.
14. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997-2008.
15. Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin. 1990;40(4):199-209.
16. Brincker H, Rose C, Rank F, et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 1987;5(11):1771-1778.
17. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365-2370.
18. Stone ER, Slack RS, Novielli A, et al. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant Adriamycin and Cytoxan (AC) and Adriamycin and Cytoxan followed by Taxol (AC+T) in early stage breast cancer. Breast Cancer Res Treat. 2000;64(1):224. Abstract.
19. Swain SM, Land SR, Sundry R, et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) docetaxel (T) arm of NSABP B-30: preliminary results. J Clin Oncol. (2005 ASCO Meeting Abstract). 2005;23(16S):537.
20. Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575-1579.
21. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-1729.
22. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352(9132):903-942.
23. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 2001;(30):67-71.
24. LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007; 369(9574):1711-1723.
25. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17(9):2659-2669.
26. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
27. Holmberg L, Anderson H, HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453-455.
28. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009;374(9697):1243-1251.
29. Rossing MA, Cushing-Haugen KL, Wicklund KG, et al. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2548-2556.
30. Mørch LS, Løkkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer. JAMA. 2009;302(3):298-305.
31. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf). 1985;22(3):293-312.
32. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002;77(11):1207-1218.
33. Li C, Samsioe G, Borgfeldt C, et al. Menopause-related symptoms: what are the background factors? a prospective population-based cohort study of Swedish women (The Women's Health in Lund Area Study). Am J Obstet Gynecol. 2003;189(6):1646-1653.
34. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16(2):495-500.
35. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br J Med. 1974;1(5905):409-412.
36. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000;132(10):788-793.
37. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337-345.
38. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818-824.
39. Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric. 2009;12(4):310-318.
40. Evans ML, Pritts E, VittinghoffE, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005;105(1):161-166.
41. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059-2063.
42. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28(35):5147-5152.
43. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011;29(29):3862-3868.
44. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46.
45. Bardia A, Tleyjeh IM, Cerhan JR, et al. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008;83(1):23-34.
46. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20(6):1578-1583.
47. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23(28):6919-6930.
48. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010;28(20):3278-3283.
49. Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol. 2008;9(6):523-532.
50. Bordet MF, Colas A, Marijnen P, et al. Treating hot flushes in menopausal women with homeopathic treatment-results of an observational study. Homeopathy. 2008;97(1):10-15.
51. Jacobs J, Herman P, Heron K, et al. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial. J Altern Complement Med. 2005;11(1):21-27.
52. Thompson EA, Reilly D. The homeopathic approach to the treatment of symptoms of estrogen withdrawal in breast cancer patients: a prospective observational study. Homeopathy. 2003;92(3):131-134.
53. Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? a double-blind, placebo-controlled trial. Fertil Steril. 1997;68(6):981-986.
54. Lau CB, Ho TC, Chan TW, Kim SC. Use of dong quai (Angelica sinensis) to treat peri-or postmenopausal symptoms in women with breast cancer: is it appropriate? Menopause. 2005;12(6):734-740.
55. Hernández Muñoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003;44 (suppl 1): S59-S65.
56. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19(10):2739-2745.
57. Chow EC, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust. 2008;188(7):420-422.
58. Tham DM, Gardner CD, Haskell WL. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 1998;83(7):2223-2235.
59. Molteni A, Brizio-Molteni L, Persky V. In vitro hormonal effects of soybean isoflavones. J Nutr. 1995;125(3 suppl):751S-756S.
60. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Group Trial. J Clin Oncol. 2000;18(5):1068-1074.
61. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002;20(6):1449-1455.
62. Carson JW, Carson KM, Porter LS, et al. Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer. 2009;17(10):1301-1309.
63. Chattha R, Raghuram N, Venkatram P, Hongasandra NR. Treating the climacteric symptoms in Indian women with an integrated approach to yoga therapy: a randomized control study. Menopause. 2008;15(5):862-870.
64. Kouno Y. Menopausal symptoms and life style. Obstet Gynecol Ther. 1998;76:196-201.
65. Ueda M, Tokunaga M. Effects of exercise experienced in the life stages on climacteric symptoms for females. J Physiol Anthropol Appl Human Sci. 2000;19(4):181-189.
66. Slaven L, Lee C. Psychological effects of exercise among adult women: the impact of menopausal status. Psychol Health. 1994;9(4):297-303.
67. Kawakubo K, Motoki C. Menopausal disorder and exercise therapy. Gynecol Pract. 1995;44:873-877.
68. Ueda M. A 12-week structured education and exercise program improved climacteric symptoms in middle-aged women. J Physiol Anthropol Appl Human Sci. 2004;23(5):143-148.
69. Berglund G, Nystedt M, Bolund C, et al. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2001;19(11):2788-2796.
70. Malinovszky KM, Gould A, Foster E, et al. Quality of life and sexual func tion after high-dose or conventional chemotherapy for high-risk breast cancer. Br J Cancer. 2006;95(12):1626-1631.
71. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004;15(8):753-760.
72. Shell JA. Evidence-based practice for symptom management in adults with cancer: sexual dysfunction. Oncol Nurs Forum. 2002;29(1):53-66.
73. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994;61(1):178-180.
74. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009;12(2):91-105.
75. Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010;26(6):404-412.
76. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 2002;9(3):179-187.
77. Howell A, Cuzick J, Baum M, et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
78. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522.
79. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12(3):447-453.
80. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265(14):1861-1867.
81. Roychoudhuri R, Robinson D, Putcha V, et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;7:9.
82. Valagussa P, Zambetti M, Biasi S, et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994;5(3):209-216.
83. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328(20):1444-1449.
84. Marty M, Espié M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/ metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17(4):614-622.
85. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med. 1995;123(9):673-675.
86. Irwin ML, Alvarez-Reeves M, Cadmus L, et al. Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring). 2009;17(8):1534-1541.
87. Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1672-1680.
88. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005;93(suppl 1):S16-S22.
89. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-4057.
90. Headley JA, Theriault RL, LeBlanc AD, et al. Pilot study of bone mineral density in patients treated with adjuvant chemotherapy. Cancer Invest. 1998; 16(1):6-11.
91. Body JJ. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol. 2010;21(suppl 7):vii180-vii185.
92. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 2007;18(suppl 8):viii26-viii35.
93. Wallace BA, Cumming RG. Systematic review of randomized trials of the effect of exercise on bone mass in pre-and postmenopausal women. Calcif Tissue Int. 2000;67(1):10-18.
94. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol. 2002;450(1):11-17.
95. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459-468.
96. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25(7):820-828.
97. Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12(9):2759-2766.
98. Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric. 2006;9(1):49-58.